InvestorsHub Logo
Followers 272
Posts 53209
Boards Moderated 3
Alias Born 08/16/2008

Re: MiamiGent post# 86

Monday, 05/13/2024 11:43:24 AM

Monday, May 13, 2024 11:43:24 AM

Post# of 91
AICU AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
6:05 AM ET May-13-2024
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for option exercise and milestones of up to approximately $2.1 billion
ACI-24.060 ABATE Phase 2 trial on track to report Abeta-PET imaging results in Q2 2024, evaluating amyloid plaque reduction after 6 months of anti-Abeta active immunotherapy
ACI-7104.056 VacSYn Phase 2 trial of anti-a-syn active immunotherapy in Parkinson’s disease (PD) on track for safety and immunogenicity interim data in H2 2024
Three-year cash runway with CHF 104.8 million at quarter end, plus $100 million upfront from Takeda and the anticipated ACI-35.030-related CHF 25 million milestone
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ACIU News